Related Experiment Video
Updated: Aug 14, 2026
07:33
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
[Lymphokine-activated killer (LAK) adoptive immunotherapy: optimal method for large-scale LAK induction]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|June 1, 1987
Summary
Large-scale induction of lymphokine-activated killer (LAK) cells for immunotherapy requires optimal conditions. Monocytes and specific serum concentrations in roller bottles enhance LAK cell production for cancer treatment.
Area of Science:
- Immunology
- Cell Therapy
- Cancer Research
Context:
- Adoptive immunotherapy using lymphokine-activated killer (LAK) cells presents a promising avenue for treating malignant diseases.
- A significant challenge in LAK therapy is the efficient induction of the required large numbers of LAK cells (10^11 to 10^12).
Purpose:
- To determine optimal conditions for large-scale induction of LAK cells for adoptive immunotherapy.
- To investigate the role of monocytes, serum concentration, and culture vessels in LAK cell generation.
Summary:
- Monocytes, separated via counterflow centrifugal elutriation, significantly enhanced LAK cell induction from lymphocytes.
- Optimal LAK activity was achieved with mononuclear cells (MNCs) containing approximately 20% monocytes.
- Culture in RPMI 1640 with at least 5% human AB serum and the use of roller bottles (4 x 10^6 cells/ml) were identified as optimal for large-scale LAK induction.
- LAK cell administration on the 3rd and 4th day of culture supports weekly adoptive therapy.
Impact:
- Establishes optimized protocols for the large-scale production of LAK cells, addressing a critical bottleneck in LAK therapy.
- Provides a foundation for the clinical application of LAK cell adoptive immunotherapy for various cancers.
- Facilitates the advancement of cell-based cancer treatments through improved manufacturing processes.
